First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia - Ravandi, F; O’Brien, S; Thomas, D (Blood, 2010)
et al.